<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437722</url>
  </required_header>
  <id_info>
    <org_study_id>SPL7013-014</org_study_id>
    <nct_id>NCT01437722</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)</brief_title>
  <official_title>A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGelÂ®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Starpharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Starpharma Pty Ltd</source>
  <brief_summary>
    <textblock>
      The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the
      prevention of recurrence of bacterial vaginosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women who have experienced a recurrent episode of BV as a measure of efficacy</measure>
    <time_frame>Day 112 +/- 5</time_frame>
    <description>Number of women who have BV as measured by subject-reported symptoms and Amsel's Criteria</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Recurrent Bacterial Vaginosis (BV)</condition>
  <arm_group>
    <arm_group_label>1% SPL7013 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3% SPL7013 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% SPL7013 Gel</intervention_name>
    <description>vaginal gel</description>
    <arm_group_label>1% SPL7013 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% SPL7013 Gel</intervention_name>
    <description>vaginal gel</description>
    <arm_group_label>3% SPL7013 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>vaginal gel</description>
    <arm_group_label>placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-45 years with a history of recurrent BV, defined as at least 3
             documented episodes in the previous 12 months (including the current episode).

          -  Current episode of BV as defined by subject-reported symptoms and Amsel's Criteria

          -  Otherwise healthy

        Exclusion Criteria:

          -  No active STIs and/or current UTI

          -  Previous exposure to SPL7013 Gel

          -  A Papanicolaou (Pap) smear result considered to be clinically significant (ie, high
             grade cervical intraepithelial squamous lesions [HSIL] on cytology or cervical
             intraepithelial neoplasia [CIN] grades of CIN2 or CIN3 on histology) in the previous 2
             years or in accordance with local treatment guidelines.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Paull, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Starpharma Pty Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <disposition_first_submitted>October 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 25, 2012</disposition_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BV</keyword>
  <keyword>Bacterial vaginosis</keyword>
  <keyword>recurrent</keyword>
  <keyword>SPL7013 Gel</keyword>
  <keyword>VivaGel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

